Group I and group II metabotropic glutamate receptor allosteric modulators as novel potential antipsychotics

Highlights • mGlu5 PAMs treat positive, negative, and cognitive symptoms in animal models. • Genetic mutations in mGlu1 have been identified in some schizophrenic patients. • Early clinical data showed efficacy of mGlu2/3 agonists, but later trials did not. • mGlu2 PAMs are now in clinical developme...

Full description

Saved in:
Bibliographic Details
Published in:Current opinion in pharmacology 2015-02, Vol.20, p.40-45
Main Authors: Walker, Adam G, Conn, P Jeffrey
Format: Article
Language:English
Subjects:
Allosteric Regulation - drug effects
Animals
Antipsychotic Agents - pharmacology
Drug Design
Humans
Internal Medicine
Medical Education
Molecular Targeted Therapy
Receptors, Metabotropic Glutamate - drug effects
Receptors, Metabotropic Glutamate - metabolism
Schizophrenia - drug therapy
Schizophrenia - physiopathology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • mGlu5 PAMs treat positive, negative, and cognitive symptoms in animal models. • Genetic mutations in mGlu1 have been identified in some schizophrenic patients. • Early clinical data showed efficacy of mGlu2/3 agonists, but later trials did not. • mGlu2 PAMs are now in clinical development. • Mutations in mGlu3 have been identified in schizophrenics and may affect cognition.
ISSN:1471-4892
1471-4973
DOI:10.1016/j.coph.2014.11.003